The posterior hairline may be low and the neck webbed and/or short.
The skeletal features may include thorax abnormalities of pectus excavatum and/or carinatum, and flat, shield, or funnel chest. Cubitus valgus, kyphosis, scoliosis, vertebral anomalies, genuavalga, pesplanus, and syndactyly may also be present. 7 Cardiovascular abnormalities occur in 50-90% of individuals with Noonan syndrome. [8] [9] [10] The most frequent cardiac lesions are pulmonic stenosis (27-65%), 5, 11 hypertrophic cardiomyopathy (9-25%), 10, 11 and atrial septal defect. Other cardiovascular abnormalities described in
Noonan syndrome include ventricular septal defect, patent ductus arteriosus, coarctation of the aorta, mitral valve abnormalities, partial atrio-ventricular canal, dilated ascending aorta, and severe aortic valve stenosis. Additionally, an unusual electrocardiogram (EKG) pattern has been described in Noonan syndrome regardless of the presence or absence of an anatomical cardiac defect, characterized by left axis deviation, an abnormal dominant S wave over the left precordium, and an abnormal Q wave. 12 Coagulopathies have been described in approximately one-third of patients with Noonan syndrome, 13 though two-thirds of patients will describe abnormal bleeding and/or increased bruising. 14 However, other significant manifestations of lymphatic abnormalities may include malabsorption secondary to intestinal lymphangiectasia, lymphangiectasia of the lungs, lymphedema of the scrotum or vulva, lymph leakage from skin fistulas, and chylothorax. 5 Lymphedema may develop in adolescence and adulthood. 20 Renal anomalies in Noonan syndrome seem to be less common (10-11%) than other comorbidities and are usually of little significance. 17, 21, 22 Solitary kidney, renal pelvis dilation, and duplicated collecting system are some of the findings. Cryptorchidism commonly occurs (up to 80%) in boys and may require surgical attention. 17 Other clinical co-morbidities may include Arnold Chiari malformation, seizures (13%), 17 hearing difficulties, and developmental delays.
Genetics
The Table 1 ). At present, some of these genes are associated with more than one syndrome (PTPN11, RAF1, and KRAS). 40 mutations. 27, 35 Individuals with mutations in the CR2 domain in exon 7 of RAF1 have a high incidence of hypertrophic cardiomyopathy (80-95%). 37, 38 The mutation in PTPN11 of 218C→T (Thr73Ile) is correlated with a high risk of JMML. [41] [42] [43] The 922A→G (Asn308Asp) mutation in exon 8 of PTPN11
appears to be associated with normal intelligence.
10,27
Growth Approximately 50-70% of individuals with Noonan syndrome are thought to have short stature. 1, 7, 17 Although short stature is one of the main characteristics of this condition, some individuals with Noonan syndrome will have completely normal growth and stature. Birth weight and length are typically normal, but there is subsequent retardation of height, weight, and bone development such that heights and weights are below the third centile. The mean delay of bone age behind chronological age is about two years. 17, 44 Puberty is frequently delayed in both sexes, with a decreased pubertal growth spurt. 44 Noonan-specific growth charts have been published. 44, 45 Mean adult heights for females have been reported as 152.7cm 44 and 153.3cm 5 and for males as 162.5cm 44 and 169.8cm. 5 It is important to recognize that these adult height data are in predominantly European populations when using them for individuals with Noonan syndrome from other populations, whose mean population height may differ. In a review of heights in 73 adults in North America with Noonan syndrome, Studies with GH therapy in Noonan syndrome have shown that short-term growth acceleration has been comparable to that seen in Turner syndrome.
48,60
The NCGS enrolled 150 pre-pubertal and pubertal children (53 girls) with to the appearance of advancing bone age in children with Noonan syndrome with a very delayed bone age (less than -3SD) at the start of treatment. This change in bone age relative to the degree of bone age delay was reported in 1996, when the ratio of the change in bone age relative to the change in height age for children with Noonan syndrome was compared with the change seen in those with Turner syndrome and idiopathic GH deficiency (IGHD). 48 It was demonstrated that bone age does not disproportionately advance in
Noonan syndrome compared with the bone age delays seen in the other two groups. Because patients with Noonan syndrome have a more delayed bone age, bone age appears to advance at an accelerated rate only due to normalization of bone age under GH therapy. Significant improvements in adult height with GH use in individuals with Noonan syndrome are further evidence that bone age does not advance inordinately. 56, [61] [62] [63] [64] [65] Data on the final or near-final height of patients must be assessed in order to consider the efficacy of GH in Noonan syndrome. Recently, there has been an increasing amount of data concerning adult height in patients with Noonan syndrome treated with GH; these data are summarized in Table 2 . Although Considering the involvement of the gene mutations in Noonan syndrome in the Ras/MAPK signal transduction pathway, several studies have looked at GH responsiveness relative to the presence or absence of a mutation in the PTPN11
gene. Initial short-term data suggested that mutation-positive patients responded 'less efficiently' to GH than mutation-negative patients. 54 However, longer-term data comparing adult heights between mutation-positive and mutation-negative patients who have been treated with GH demonstrate that there is no difference in outcome. 65 This difference in GH response between children with and without mutations in PTPN11 may therefore be significant only in the short-term, and may diminish over long-term GH therapy.
Conclusions
Noonan syndrome is a clinically and genetically heterogeneous condition 
